Background: The RNA-dependent RNA polymerase (RdRp) inhibitors, molnupiravir and
VV116, have the potential to maximize clinical benefits in the oral treatment of COVID-19 …

A simple fast ecofriendly spectrophotometric method was developed and applied
successfully for accurate and sensitive assessment of Molnupiravir (MOL) in pure bulk …

Background: Molnupiravir is a ribonucleoside analog and exhibits its antiviral mechanism by
inhibiting replication. Preclinical studies have been reported that support the role of …

Background: As the COVID era unfolds, researchers reveal that rapid changes in viral
genetic material allow viruses to circumvent challenges triggered by the host immune …

COVID-19 is an infectious disease that is caused by coronavirus SARS-CoV-2. As the time
passed it became clear that, aside from the vaccines, other efficient methods of fighting the …

Objectives We aimed to harness IDentif. AI 2.0, a clinically actionable AI platform to rapidly
pinpoint and prioritize optimal combination therapy regimens against COVID-19. Methods A …

COVID-19 drug development has largely focused on repurposing, either through single
agent or combination therapy 1–5. To date, clinical trial outcomes of the repurposed …

Background: Open Access Comment Nafamostat-Mediated Inhibition of SARS-CoV-2
Ribosomal Frameshifting Is Insufficient to Impair Viral Replication in Vero Cells. Comment …

Background: Treatment with antiviral drugs for non-severe, early time from onset, adult
outpatients with Coronavirus Disease 2019 (COVID-19) had not been established in 2021 …

Molnupiravir (MOL) is an orally absorbed prodrug of the ribonucleoside analogue N-
hydroxycytidine, which has in vitro activity against several coronaviruses, including SARS …